Retinitis Pigmentosa Treatment Market : Growth factor with key drivers, industry research, regional forecast – Jewish Life News

QY Research as of late produced a research report titled, Retinitis Pigmentosa Treatment . The research report speak about the potential development openings that exist in the worldwide market. The report is broken down on the basis of research procedures procured from historical and forecast information. The global Retinitis Pigmentosa Treatment market is relied upon to develop generously and flourish as far as volume and incentive during the gauge time frame. The report will give a knowledge about the development openings and controls that will build the market. Pursuers can increase important perception about the eventual fate of the market.

Key companies that are operating in the global Retinitis Pigmentosa Treatment market are: Astellas Pharma Inc., Caladrius Biosciences, Inc., Dompe Farmaceutici S.p.A., Genable Technologies Limited, Genethon, GenSight Biologics S.A., Grupo Ferrer Internacional, S.A., ID Pharma Co., Ltd., InFlectis BioScience, International Stem Cell Corporation, Ionis Pharmaceuticals, Inc., Ms Science Corporation, Mimetogen Pharmaceuticals Inc., Nanovector s.r.l., Orphagen Pharmaceuticals, Inc., etc.

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1786433/covid-19-impact-on-retinitis-pigmentosa-treatment-market

Segmental Analysis

The report incorporates significant sections, for example, type and end user and a variety of segments that decide the prospects of the market. Each type provide data with respect to the business esteem during the conjecture time frame. The application area likewise gives information by volume and consumption during the estimate time frame. The comprehension of this segment direct the readers in perceiving the significance of variables that shape the market development.

Global Retinitis Pigmentosa Treatment Market Segment By Type:

, BNP-RP, Cenegermin, CPK-850, Cutamesine, FAB-111, Others

Global Retinitis Pigmentosa Treatment Market Segment By Application:

, Hospital, Clinic, Homecare

Competitive Landscape

The report incorporates various key players and producers working in the local and worldwide market. This segment shows the procedures received by players in the market to remain ahead in the challenge. New patterns and its reception by players assist readers with understanding the elements of the business and how it very well may be utilized to their own benefit. The readers can likewise recognize the strides of players to comprehend the global market better.

Key companies operating in the global Retinitis Pigmentosa Treatment market include Astellas Pharma Inc., Caladrius Biosciences, Inc., Dompe Farmaceutici S.p.A., Genable Technologies Limited, Genethon, GenSight Biologics S.A., Grupo Ferrer Internacional, S.A., ID Pharma Co., Ltd., InFlectis BioScience, International Stem Cell Corporation, Ionis Pharmaceuticals, Inc., Ms Science Corporation, Mimetogen Pharmaceuticals Inc., Nanovector s.r.l., Orphagen Pharmaceuticals, Inc., etc.

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1786433/covid-19-impact-on-retinitis-pigmentosa-treatment-market

TOC

1.1 Research Scope1.2 Market Segmentation1.3 Research Objectives1.4 Research Methodology1.4.1 Research Process1.4.2 Data Triangulation1.4.3 Research Approach1.4.4 Base Year1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections1.5.2 Covid-19 Impact: Commodity Prices Indices1.5.3 Covid-19 Impact: Global Major Government Policy1.6 The Covid-19 Impact on Retinitis Pigmentosa Treatment Industry1.7 COVID-19 Impact: Retinitis Pigmentosa Treatment Market Trends 2 Global Retinitis Pigmentosa Treatment Quarterly Market Size Analysis2.1 Retinitis Pigmentosa Treatment Business Impact Assessment COVID-192.1.1 Global Retinitis Pigmentosa Treatment Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-20262.2 Global Retinitis Pigmentosa Treatment Quarterly Market Size 2020-20212.3 COVID-19-Driven Market Dynamics and Factor Analysis2.3.1 Drivers2.3.2 Restraints2.3.3 Opportunities2.3.4 Challenges 3 Quarterly Competitive Assessment, 20203.1 By Players, Global Retinitis Pigmentosa Treatment Quarterly Market Size, 2019 VS 20203.2 By Players, Retinitis Pigmentosa Treatment Headquarters and Area Served3.3 Date of Key Players Enter into Retinitis Pigmentosa Treatment Market3.4 Key Players Retinitis Pigmentosa Treatment Product Offered3.5 Mergers & Acquisitions, Expansion Plans 4 Impact of Covid-19 on Retinitis Pigmentosa Treatment Segments, By Type4.1 Introduction1.4.1 BNP-RP1.4.2 Cenegermin1.4.3 CPK-8501.4.4 Cutamesine1.4.5 FAB-1111.4.6 Others4.2 By Type, Global Retinitis Pigmentosa Treatment Market Size, 2019-2021 5 Impact of Covid-19 on Retinitis Pigmentosa Treatment Segments, By Application5.1 Overview5.5.1 Hospital5.5.2 Clinic5.5.3 Homecare5.2 By Application, Global Retinitis Pigmentosa Treatment Market Size, 2019-20215.2.1 By Application, Global Retinitis Pigmentosa Treatment Market Size by Application, 2019-2021 6 Geographic Analysis6.1 Introduction6.2 North America6.2.1 Macroeconomic Indicators of US6.2.2 US6.2.3 Canada6.3 Europe6.3.1 Macroeconomic Indicators of Europe6.3.2 Germany6.3.3 France6.3.4 UK6.3.5 Italy6.4 Asia-Pacific6.4.1 Macroeconomic Indicators of Asia-Pacific6.4.2 China6.4.3 Japan6.4.4 South Korea6.4.5 India6.4.6 ASEAN6.5 Rest of World6.5.1 Latin America6.5.2 Middle East and Africa 7 Company Profiles7.1 Astellas Pharma Inc.7.1.1 Astellas Pharma Inc. Business Overview7.1.2 Astellas Pharma Inc. Retinitis Pigmentosa Treatment Quarterly Revenue, 20207.1.3 Astellas Pharma Inc. Retinitis Pigmentosa Treatment Product Introduction7.1.4 Astellas Pharma Inc. Response to COVID-19 and Related Developments7.2 Caladrius Biosciences, Inc.7.2.1 Caladrius Biosciences, Inc. Business Overview7.2.2 Caladrius Biosciences, Inc. Retinitis Pigmentosa Treatment Quarterly Revenue, 20207.2.3 Caladrius Biosciences, Inc. Retinitis Pigmentosa Treatment Product Introduction7.2.4 Caladrius Biosciences, Inc. Response to COVID-19 and Related Developments7.3 Dompe Farmaceutici S.p.A.7.3.1 Dompe Farmaceutici S.p.A. Business Overview7.3.2 Dompe Farmaceutici S.p.A. Retinitis Pigmentosa Treatment Quarterly Revenue, 20207.3.3 Dompe Farmaceutici S.p.A. Retinitis Pigmentosa Treatment Product Introduction7.3.4 Dompe Farmaceutici S.p.A. Response to COVID-19 and Related Developments7.4 Genable Technologies Limited7.4.1 Genable Technologies Limited Business Overview7.4.2 Genable Technologies Limited Retinitis Pigmentosa Treatment Quarterly Revenue, 20207.4.3 Genable Technologies Limited Retinitis Pigmentosa Treatment Product Introduction7.4.4 Genable Technologies Limited Response to COVID-19 and Related Developments7.5 Genethon7.5.1 Genethon Business Overview7.5.2 Genethon Retinitis Pigmentosa Treatment Quarterly Revenue, 20207.5.3 Genethon Retinitis Pigmentosa Treatment Product Introduction7.5.4 Genethon Response to COVID-19 and Related Developments7.6 GenSight Biologics S.A.7.6.1 GenSight Biologics S.A. Business Overview7.6.2 GenSight Biologics S.A. Retinitis Pigmentosa Treatment Quarterly Revenue, 20207.6.3 GenSight Biologics S.A. Retinitis Pigmentosa Treatment Product Introduction7.6.4 GenSight Biologics S.A. Response to COVID-19 and Related Developments7.7 Grupo Ferrer Internacional, S.A.7.7.1 Grupo Ferrer Internacional, S.A. Business Overview7.7.2 Grupo Ferrer Internacional, S.A. Retinitis Pigmentosa Treatment Quarterly Revenue, 20207.7.3 Grupo Ferrer Internacional, S.A. Retinitis Pigmentosa Treatment Product Introduction7.7.4 Grupo Ferrer Internacional, S.A. Response to COVID-19 and Related Developments7.8 ID Pharma Co., Ltd.7.8.1 ID Pharma Co., Ltd. Business Overview7.8.2 ID Pharma Co., Ltd. Retinitis Pigmentosa Treatment Quarterly Revenue, 20207.8.3 ID Pharma Co., Ltd. Retinitis Pigmentosa Treatment Product Introduction7.8.4 ID Pharma Co., Ltd. Response to COVID-19 and Related Developments7.9 InFlectis BioScience7.9.1 InFlectis BioScience Business Overview7.9.2 InFlectis BioScience Retinitis Pigmentosa Treatment Quarterly Revenue, 20207.9.3 InFlectis BioScience Retinitis Pigmentosa Treatment Product Introduction7.9.4 InFlectis BioScience Response to COVID-19 and Related Developments7.10 International Stem Cell Corporation7.10.1 International Stem Cell Corporation Business Overview7.10.2 International Stem Cell Corporation Retinitis Pigmentosa Treatment Quarterly Revenue, 20207.10.3 International Stem Cell Corporation Retinitis Pigmentosa Treatment Product Introduction7.10.4 International Stem Cell Corporation Response to COVID-19 and Related Developments7.11 Ionis Pharmaceuticals, Inc.7.11.1 Ionis Pharmaceuticals, Inc. Business Overview7.11.2 Ionis Pharmaceuticals, Inc. Retinitis Pigmentosa Treatment Quarterly Revenue, 20207.11.3 Ionis Pharmaceuticals, Inc. Retinitis Pigmentosa Treatment Product Introduction7.11.4 Ionis Pharmaceuticals, Inc. Response to COVID-19 and Related Developments7.12 Ms Science Corporation7.12.1 Ms Science Corporation Business Overview7.12.2 Ms Science Corporation Retinitis Pigmentosa Treatment Quarterly Revenue, 20207.12.3 Ms Science Corporation Retinitis Pigmentosa Treatment Product Introduction7.12.4 Ms Science Corporation Response to COVID-19 and Related Developments7.13 Mimetogen Pharmaceuticals Inc.7.13.1 Mimetogen Pharmaceuticals Inc. Business Overview7.13.2 Mimetogen Pharmaceuticals Inc. Retinitis Pigmentosa Treatment Quarterly Revenue, 20207.13.3 Mimetogen Pharmaceuticals Inc. Retinitis Pigmentosa Treatment Product Introduction7.13.4 Mimetogen Pharmaceuticals Inc. Response to COVID-19 and Related Developments7.14 Nanovector s.r.l.7.14.1 Nanovector s.r.l. Business Overview7.14.2 Nanovector s.r.l. Retinitis Pigmentosa Treatment Quarterly Revenue, 20207.14.3 Nanovector s.r.l. Retinitis Pigmentosa Treatment Product Introduction7.14.4 Nanovector s.r.l. Response to COVID-19 and Related Developments7.15 Orphagen Pharmaceuticals, Inc.7.15.1 Orphagen Pharmaceuticals, Inc. Business Overview7.15.2 Orphagen Pharmaceuticals, Inc. Retinitis Pigmentosa Treatment Quarterly Revenue, 20207.15.3 Orphagen Pharmaceuticals, Inc. Retinitis Pigmentosa Treatment Product Introduction7.15.4 Orphagen Pharmaceuticals, Inc. Response to COVID-19 and Related Developments 8 Key Findings 9 Appendix9.1 About US9.2 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

View original post here:
Retinitis Pigmentosa Treatment Market : Growth factor with key drivers, industry research, regional forecast - Jewish Life News

COVID-19 Impact on Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size, Status and Forecast 2020-2026 – Jewish Life News

In this report, the COVID-19 Impact on Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market is valued at USD XX million in 2019 and is expected to reach USD XX million by the end of 2026, growing at a CAGR of XX% between 2019 and 2026. COVID-19 Impact on Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market has been broken down by major regions, with complete market estimates on the basis of products/applications on a regional basis.

Browse full research report at https://www.crystalmarketreport.com/covid-19-impact-on-global-stem-cell-and-platelet-rich-plasma-prp-alopecia-therapies-market-size-status-and-forecast-2020-2026

Platelet-rich plasma (PRP) has emerged as a new treatment modality in regenerative plastic surgery, and preliminary evidence suggests that it might have a beneficial role in hair regrowth.

Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market in 2020.

COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

This report also analyses the impact of Coronavirus COVID-19 on the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies industry.

Based on our recent survey, we have several different scenarios about the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ xx million in 2019. The market size of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market in terms of revenue.

Players, stakeholders, and other participants in the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market will be able to gain the upper hand as they use the report as a powerful resource. For this version of the report, the segmental analysis focuses on revenue and forecast by each application segment in terms of revenue and forecast by each type segment in terms of revenue for the period 2015-2026.

Regional and Country-level Analysis

The report offers an exhaustive geographical analysis of the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market, covering important regions, viz, North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.

The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.

Competition Analysis

In the competitive analysis section of the report, leading as well as prominent players of the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market.

The following players are covered in this report:

Orange County Hair Restoration Center

Hair Sciences Center of Colorado

Anderson Center for Hair

Evolution Hair Loss Institute

Savola Aesthetic Dermatology Center

Virginia Surgical Center

Hair Transplant Institute of Miami

Colorado Surgical Center & Hair Institute

Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Breakdown Data by Type

Platelet Rich Plasma Injections

Stem Cell Therapy

Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Breakdown Data by Application

Dermatology Clinics

Hospitals

Browse full research report at https://www.crystalmarketreport.com/covid-19-impact-on-global-stem-cell-and-platelet-rich-plasma-prp-alopecia-therapies-market-size-status-and-forecast-2020-2026

Reasons to Buy This Research Report

About Crystal Market Reports

Crystal Market Reports is a distributor of market research spanning 160 industries. Our extensive database consists of over 400,000 quality publications sourced from 400 plus publishers, this puts our research specialists in the unique position of been able to offer truly unbiased advice on what research provides the most valuable insights.

Contact Info.:-

Address: 911 Central Avenue #268Albany New York 12206Email: [emailprotected]Phone: 1-518-730-1569Web: https://www.crystalmarketreport.com

Continued here:
COVID-19 Impact on Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size, Status and Forecast 2020-2026 - Jewish Life News

Global Myelofibrosis Treatment Market to Register Growth in Incremental Opportunity During the Forecast Period 2016 2022 – Cole of Duty

In the current situation of restricted movement and reduced workforce, (due to COVID-19 Pandemic) new technologies have been developed to provide end-to-end automation in different sectors such as food processing. Automated systems are hired by the companies to ensure continued supply and manufacturing of products with the least manual interference

The advent of Health Information Technology (HIT) components such as electronic health records (EHR), hospital information systems (HIS), picture archiving and communication systems (PACS), and vendor neutral archives (VNA) has had just as transformational an impact on the overall healthcare sector as the concerns regarding security and privacy. Data theft, undue access to personal health records, and cyber-attacks are very real threats that the healthcare sector faces today.

Myelofibrosis or osteomyelofibrosis is a myeloproliferative disorder which is characterized by proliferation of abnormal clone of hematopoietic stem cells. Myelofibrosis is a rare type of chronic leukemia which affects the blood forming function of the bone marrow tissue. National Institute of Health (NIH) has listed it as a rare disease as the prevalence of myelofibrosis in UK is as low as 0.5 cases per 100,000 population. The cause of myelofibrosis is the genetic mutation in bone marrow stem cells. The disorder is found to occur mainly in the people of age 50 or more and shows no symptoms at an early stage. The common symptoms associated with myelofibrosis include weakness, fatigue, anemia, splenomegaly (spleen enlargement) and gout. However, the disease progresses very slowly and 10% of the patients eventually develop acute myeloid leukemia. Treatment options for myelofibrosis are mainly to prevent the complications associated with low blood count and splenomegaly.

To Understand How Our Report Information Can Bring Difference, Ask for a brochure @https://www.persistencemarketresearch.com/samples/11341

The global market for myelofibrosis treatment is expected to grow moderately due to low incidence of a disease. However, increasing incidence of genetic disorders, lifestyle up-gradation and rise in smoking population are the factors which can boost the growth of global myelofibrosis treatment market. The high cost of therapy will the growth of global myelofibrosis treatment market.

The global market for myelofibrosis treatment is segmented on basis of treatment type, end user and geography:

As myelofibrosis is considered as non-curable disease treatment options mainly depend on visible symptoms of a disease. Primary stages of the myelofibrosis are treated with supportive therapies such as chemotherapy and radiation therapy. However, there are serious unmet needs in myelofibrosis treatment market due to lack of disease modifying agents. Approval of JAK1/JAK2 inhibitor Ruxolitinib in 2011 is considered as a breakthrough in myelofibrosis treatment. Stem cell transplantation for the treatment of myelofibrosis also holds tremendous potential for market growth but high cost of therapy is foreseen to limits the growth of the segment.

Looking for Exclusive Market Insights from Business Experts? Request a Custom Report here @https://www.persistencemarketresearch.com/request-customization/11341

On the basis of treatment type, the global myelofibrosis treatment market has been segmented into blood transfusion, chemotherapy, androgen therapy and stem cell or bone marrow transplantation. Chemotherapy segment is expected to contribute major share due to easy availability of chemotherapeutic agents. Ruxolitinib is the only chemotherapeutic agent approved by the USFDA specifically for the treatment of myelofibrosis, which will drive the global myelofibrosis treatment market over the forecast period.

Geographically, global myelofibrosis treatment market is segmented into five regions viz. North America, Latin America, Europe, Asia Pacific and Middle East & Africa. Northe America is anticipated to lead the global myelofibrosis treatment market due to comparatively high prevalence of the disease in the region.

Some of the key market players in the global myelofibrosis treatment market are Incyte Corporation, Novartis AG, Celgene Corporation, Mylan Pharmaceuticals Ulc., Bristol-Myers Squibb Company, Eli Lilly and Company, Taro Pharmaceuticals Inc., AllCells LLC, Lonza Group Ltd., ATCC Inc. and others.

The report covers exhaustive analysis on:

Regional analysis includes

Report Highlights:

Our unmatched research methodologies set us apart from our competitors. Heres why:PMRs set of research methodologies adhere to the latest industry standards and are based on sound surveys.We are committed to preserving the objectivity of our research.Our analysts customize the research methodology according to the market in question in order to take into account the unique dynamics that shape the industry.Our proprietary research methodologies are designed to accurately predict the trajectory of a particular market based on past and present data.PMRs typical operational model comprises elements such as distribution model, forecast of market trends, contracting and expanding technology applications, pricing and transaction model, market segmentation, and vendor business and revenue model.

Read more:
Global Myelofibrosis Treatment Market to Register Growth in Incremental Opportunity During the Forecast Period 2016 2022 - Cole of Duty

COVID-19 treatments are a better bet than a vaccine – Stockhead

COVID-19 vaccines are driving markets but treatments are where most people believe a solution to the pandemic lies.

However, use of the two most famous treatments to date Gilead Sciences HIV drug remdesivir and US President Donald Trumps favourite hydroxychloroquine were initially based on hunches rather than hard data.

Scientists still dont fully understand COVID-19. Only recently did doctors discover a link between the illness and strokes in young adults, and suspect a link with a hyper-inflammatory condition in children. But they do have a better picture of what leads to death.

With the consensus forming that COVID-19 is an illness that causes both clotting and inflammation, problems likely requiring a combination of different approaches including, Morgans Financial senior analyst Derek Jellinek said this month.

Confirmatory clinical trials remain months away and doctors are still a long way from having a complete picture of the virus and its effects, so anecdotal data is informing which treatments work and which dont.

There are about 102 options that have been tried or are in trials, according to the latest count by Artis Ventures, a venture capital firm. The Milken Institute, a think tank founded by infamous 1980s junk bond king Michael Milken, counted 223 treatments under consideration.

Many in the medical and science world believe COVID-19 will become a regular, seasonal illness that pops up every year, which means treatments are likely to be worth more financially to a company than a vaccine, which typically provide more kudos than cash to their owners.

In Australia, the race to get a treatment on the market is just as hot as those for diagnostics and vaccines.

If data around the two most famous treatments, remdesivir and anti-malarial drug hydroxychloroquine, are any indication, there is unlikely to be a single magic bullet to cure COVID-19 once a person has it.

A long-awaited global study into remdesivir was released last week in the The New England Journal of Medicine, preceded by one based solely in China published a week earlier in The Lancet.

The China study found remdesivir was not associated with statistically significant clinical benefits in a 237-patient, randomised, double-blind, placebo-controlled, multi-centre trial at 10 hospitals in Hubei.

The former study, a double-blind, randomised, placebo-controlled trial of 1063 patients around the world, found remdesivir was better than a placebo in shortening the time to recovery and lowering respiratory tract infection, but needed to be used alongside other drugs.

Former Australian politician Clive Palmer was given permission to import hydroxychloroquine in April. He said in newspaper ads he brought in 32.9 million doses, which were then put in a government stockpile.

But this drug also has been broadly discredited in clinical trials as a treatment for COVID-19.

An Australian study was launched last week involving thousands of frontline doctors and nurses by the Walter and Eliza Institute of medical Research (WEHI) in Melbourne to confirm Chinese studies that suggest whether hydroxychloroquine works as a preventative.

But the World Health Organisation (WHO) yesterday paused a global study into the drug as a treatment after a Lancet review found it was associated with a high risk of death and heart problems in COVID-19 patients.

Medical professionals have learned on the job what works and that appears to be a menu of treatments, Jellinek said.

That menu includes blood plasma from survivors that contains antibodies which could neutralise the virus, as CSL (ASX:CSL) is trialing; drugs to suppress the bodys immune response which some believe goes into overdrive, which is called a cytokine storm; anticoagulants to decrease the risk of blood clots; and antivirals like remdesivir.

Drugs that dont appear to work are hydroxychloroquine, a HIV drug by AbbVie which showed no improvement in a 199-patient trial, and an arthritis drug by Regeneron and Sanofi which produced disappointing results.

While WHO labelled COVID-19 as a pneumonia-like illness in February, prompting a focus on the lungs, with a surge in ventilators, as more COVID-19 presented to hospitals it became apparent that other organs were also impacted (eg kidneys, liver, intestines, skin, even the brain) and some patients have silent hypoxia, alarmingly low oxygen levels but show no shortness of breath, which results in pneumonia, Jellinek said.

So it appears this disease is not just a disease of the virus, but something else peculiar is happening to the human body to create a dis-regulated response. And this response can last a long time in some patientsup to two, three or even six weeks.

A range of Australian companies have announced COVID-19 treatments, some of which are clearly opportunistic and others which may have some substance behind them.

Mesoblast (ASX:MSB) and Cynata (ASX:CYP) have launched clinical trials to see whether their stem cell therapies can help reduce the bodys overactive inflammatory response to the disease.

Mesoblast shareholders have benefited from the companys fast-tracked US trials, with the stock back at five-year highs.

Cancer biotech Noxopharm (ASX:NOX) also claims the active ingredient in its drug, idronoxil, inhibits an inflammatory pathway when the body goes into overdrive against COVID-19.

The US Food and Drug Administration (FDA) is currently evaluating a pre-Investigational New Drug submission from Noxopharm. A pre-IND is an introduction to the regulator, which can then decide whether to allow further studies go ahead.

Antiviral condom lube maker Starpharma (ASX:SPL) said in late April its active ingredient stopped COVID-19 infection in the lab. It has not provided any updates on this since.

There are broadly four different angles that companies and research institutions can take towards a COVID-19 treatment.

Antiviral drugs developed for other viruses include remdesivir and Hepatitis C drug danoprevir.

They also include ribonucleic acid (RNA)-specific therapies. The COVID-19 genome is made of RNA; in order to replicate it needs to copy its RNA genome so drugs inhibiting this process can help.

Antibody therapies include CSLs immunoglobulin plasma-derived treatment. These therapies are not like vaccines in that they dont confer long-lasting immunity against a disease, but instead give the body immediate tools to fight off an infection.

The issues are scale there are only so many people in the world who have had COVID-19 so only so much blood can be taken, and a survivor may not have a large number of antibodies in their blood anyway.

Cell-based therapies are those sponsored by Cynata and Mesoblast, which are primarily looking at ways to engage stem cells.

The last method is to look for drugs already in use for another illness and repurpose them for COVID-19. Hydroxychloroquine is one of these.

Researchers at the University of California in San Francisco found 47 drugs already approved by the FDA for use in the US which could have an effect on the COVID-19 virus, from antihistamines to schizophrenia drugs.

Get the latest Stock & Small Caps news and insights direct to your inbox.

You might be interested in

Continued here:
COVID-19 treatments are a better bet than a vaccine - Stockhead

Autologous Cell Therapy Market 2020 Competition by Manufacturers, Concentration Rate, Production Volume, Price|BioTime, Inc., BrainStorm Cell…

Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Autologous Cell TherapyMarket which would mention How the Covid-19 is Affecting the Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Key Regions and Proposal for Autologous Cell Therapy Market Players to battle Covid-19 Impact.

The Autologous Cell TherapyMarket report is one of the most comprehensive and important data about business strategies, qualitative and quantitative analysis of Global Market. It offers detailed research and analysis of key aspects of the Autologous Cell Therapy market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the Autologous Cell Therapy market.

Top Leading players covered in the Autologous Cell Therapy market report: BioTime, Inc., BrainStorm Cell Therapeutics, Caladrius Biosciences, Inc., Fibrocell Science, Inc., Opexa Therapeutics, Inc., Pharmicell Co., Inc., Regeneus Ltd., TiGenix NV, TxCell SA, U.S. Stem Cell, Inc., Vericel Corporation and More

Get PDF Sample Report With Impact of COVID-19 on Autologous Cell Therapy [emailprotected] https://www.marketinforeports.com/Market-Reports/Request-Sample/72169

The report offers clear guidelines for players to cement a position of strength in the global Autologous Cell Therapy market. It prepares them to face future challenges and take advantage of lucrative opportunities by providing a broad analysis of market conditions. the global Autologous Cell Therapy market will showcase a steadyCAGR in the forecast year 2020 to 2026.

Market Segment by Type covers:Bone MarrowEpidermis

Market Segment by Application covers:NeurologyOrthopedicsCancerWound HealingCVDAutoimmuneOthers

Our Complimentary Sample Autologous Cell Therapy market Report Accommodate a Brief Introduction of the research report, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology.

Inquire and Get Up to 30% DiscountBy Clicking Here!https://www.marketinforeports.com/Market-Reports/Request_discount/72169

Regions Covered in the Global Autologous Cell Therapy Market: The Middle East and Africa (GCC Countries and Egypt) North America (the United States, Mexico, and Canada) South America (Brazil etc.) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Years Considered to Estimate the Autologous Cell Therapy Market Size:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year: 2020-2026

Highlights of the Report: Accurate market size and CAGR forecasts for the period 2019-2026 Identification and in-depth assessment of growth opportunities in key segments and regions Detailed company profiling of top players of the global Autologous Cell Therapy market Exhaustive research on innovation and other trends of the global Autologous Cell Therapy market Reliable industry value chain and supply chain analysis Comprehensive analysis of important growth drivers, restraints, challenges, and growth prospects

For More Information:https://www.marketinforeports.com/Market-Reports/72169/Autologous-Cell-Therapy-market

Customization of the Report:Market Info Reports provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Get Customization of the [emailprotected]:https://www.marketinforeports.com/Market-Reports/Request-Customization/72169/Autologous-Cell-Therapy-market

Contact Us:Mr. Marcus KelCall: +1 415 658 9988 (International)+91 84 839 65921 (IND)Email: [emailprotected]Website: http://www.marketinforeports.com

The rest is here:
Autologous Cell Therapy Market 2020 Competition by Manufacturers, Concentration Rate, Production Volume, Price|BioTime, Inc., BrainStorm Cell...

Mesoblast : 3 Articles on RYONCIL GvHD Trial Results Published in BBMT – Marketscreener.com

05/25/2020 | 12:53am EDT

CLINICAL OUTCOMES USING RYONCIL (REMESTEMCEL-L) IN CHILDREN AND ADULTS WITH SEVERE INFLAMMATORY GRAFT VERSUS HOST DISEASE PUBLISHED IN THREE ARTICLES IN BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Key points:

Melbourne, Australia; May 25, 2020; and New York, USA; May 24, 2020: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in cellular medicines for inflammatory diseases, today announced that clinical outcomes of its allogeneic mesenchymal stem cell (MSC) medicine RYONCIL (remestemcel-L)in children and adults with steroid-refractoryacute graft versus host disease (GVHD) have been published in three peer-reviewedarticles and an accompanying editorial in the May issue of Biology of Blood and Marrow Transplantation, the official publication of the American Society for Transplantation and Cellular Therapy.

Mesoblast Chief Medical Officer Dr Fred Grossman said: "Results from these three trials show a consistent pattern of safety and efficacy for RYONCIL (remestemcel-L) in patients with the greatest levels of inflammation and the most severe grades of acute GVHD. These clinical outcomes provide a compelling rationale for use of remestemcel-L in children and adults with other conditions associated with severe inflammation and cytokine release, including acute respiratory distress syndrome (ARDS) and systemic vascular manifestations of COVID-19 infection."

In the accompanying editorial, Dr Jacques Galipeau, Professor and Assistant Dean of Medicine at the Stem Cell & Regenerative Medicine Center at the University of Wisconsin-Madison and Chair of the International Society of Cell and Gene Therapy (ISCT) MSC Committee, concluded that after more than a decade of clinical study involving three distinct advanced trials, it appears that remestemcel-L might well have finally met the regulatory requirements for marketing approval in the United States for steroid refractory acute GVHD in children, and it is to be determined whether this industrial MSC product will find utility for adults afflicted by acute GVHD or other indications.

The trials highlighted in the three articles all evaluated the same treatment regimen of RYONCIL, with patients receiving twice weekly intravenous infusions of 2 million cells per kg body weight over a four- week period. RYONCIL was well-tolerated in all studies with no identified safety concerns. The three trials were:

2. Study GVHD001/002: A Phase 3 single-arm trial in 55 children across 20 centers in the United States where RYONCIL was used as the first line of treatment for children who failed to respond to steroids for acute GVHD.

3. Study 280: A Phase 3 randomized placebo-controlled trial in 260 patients, including 28 children,

across 72 centers in seven countries where RYONCIL or placebo were added to second line therapy in patients with steroid-refractory acute GVHD who failed to respond to steroid treatment.

About Acute Graft Versus Host Disease

Acute GVHD occurs in approximately 50% of patients who receive an allogeneic bone marrow transplant (BMT). Over 30,000 patients worldwide undergo an allogeneic BMT annually, primarily during treatment for blood cancers, and these numbers are increasing.1 In patients with the most severe form of acute GVHD (Grade C/D or III/IV) mortality is as high as 90% despite optimal institutional standard of care.2,3 There are currently no FDA-approved treatments in the United States for children under 12 with steroid-refractory acute GVHD.

About RYONCILTM

Mesoblast's lead product candidate, RYONCIL (remestemcel-L), is an investigational therapy comprising culture-expanded mesenchymal stem cells derived from the bone marrow of an unrelated donor. It is administered to patients in a series of intravenous infusions. RYONCIL is believed to have immunomodulatory properties to counteract the inflammatory processes that are implicated in SR- aGVHD by down-regulating the production of pro-inflammatory cytokines, increasing production of anti-inflammatory cytokines, and enabling recruitment of naturally occurring anti-inflammatory cells to involved tissues.

References

About Mesoblast

Mesoblast Limited (ASX:MSB; Nasdaq:MESO) is a world leader in developing allogeneic (off-the-shelf) cellular medicines. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of commercial products and late-stage product candidates. The Company's proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

Mesoblast's Biologics License Application to seek approval of its product candidate RYONCIL (remestemcel-L) for pediatric steroid-refractory acute graft versus host disease (acute GVHD) has been accepted for priority review by the United States Food and Drug Administration (FDA), and if approved, product launch in the United States is expected in 2020. Remestemcel-L is also being developed for other inflammatory diseases in children and adults including moderate to severe acute respiratory distress syndrome. Mesoblast is completing Phase 3 trials for its product candidates for advanced heart failure and chronic low back pain. Two products have been commercialized in Japan and Europe by Mesoblast's licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets.

Mesoblast has a strong and extensive global intellectual property (IP) portfolio with protection extending through to at least 2040 in all major markets. This IP position is expected to provide the Company with substantial commercial advantages as it develops its product candidates for these conditions.

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see http://www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast

Forward-Looking Statements

This announcement includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward- looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward- looking statements include, but are not limited to, statements about the initiation, timing, progress and results of Mesoblast and its collaborators' clinical studies; Mesoblast and its collaborators' ability to advance product candidates into, enroll and successfully complete, clinical studies; the timing or likelihood of regulatory filings and approvals; and the pricing and reimbursement of Mesoblast's product candidates, if approved; the potential benefits of strategic collaboration agreements and Mesoblast's ability to maintain established strategic collaborations; Mesoblast's ability to establish and maintain intellectual property on its product candidates and Mesoblast's ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast's actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

Release authorized by the Chief Executive.

For further information, please contact:

Media

Julie Meldrum

Kristen Bothwell

T: +61 3 9639 6036

T: +1 917 613 5434

E:julie.meldrum@mesoblast.com

E:kbothwell@rubenstein.com

Investors

Schond Greenway

Paul Hughes

+212 880 2060

T: +61 3 9639 6036

E: schond.greenway@mesoblast.com

E: paul.hughes@mesoblast.com

Disclaimer

Mesoblast Limited published this content on 25 May 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 May 2020 04:52:02 UTC

Technical analysis trends MESOBLAST LIMITED

Income Statement Evolution

Here is the original post:
Mesoblast : 3 Articles on RYONCIL GvHD Trial Results Published in BBMT - Marketscreener.com

The Week Ahead In Biotech: ASCO Presentations In The Spotlight – Benzinga

Biotech stocks closed the week ended May 22 higher, with stray clinical readouts and COVID-19 drug- and vaccine-related news moving stocks in the sector.

Surface Oncology Inc (NASDAQ: SURF) was one of the biggest advancers of the week after it announced an oncology partnership with Merck & Co., Inc. (NYSE: MRK).

Sorrento Therapeutics Inc (NASDAQ: SRNE), which announced on May 15 thediscovery of100% inhibition of SARS-CoV-2, was in the news yet again this week as short sellers clamped down on the biotech, questioning the veracity of its claims.

AstraZeneca plc (NYSE: AZN) and Merck received the FDA nod for Lynparza to treat metastatic castration-resistant prostate cancerwith homologous recombination repair mutations.

The following are key catalysts forthe unfolding week:

2020 International Society of Cell and Gene Therapy, or ISCT, annual meeting: May 28-29.American Society of Clinical Oncologists 2020 Virtual Scientific Program: May 29-31.American Society for Clinical Pathology, or ASCP, 2020 Annual Meeting (virtual conference): May 29-30.

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) await the FDA verdict on their sBLA for Dupixent in pediatric eczema. (Tuesday)

Mersana Therapeutics Inc (NASDAQ: MRSN) will present interim data from the ongoing XMT-1536 Phase 1 dose expansion in patients with ovarian cancer and non-small cell lung adenocarcinoma.

See also: These 6 Coronavirus Vaccine Candidates Are The Likeliest To Succeed, Says Morgan Stanley

Friday

Mesoblast limited (NASDAQ: MESO): oral presentation of results using its allogeneic mesenchymal stem cell product candidate remestemcel-L in patients with inflammatory lung disease

Karuna Therapeutics Inc (NASDAQ: KRTX) will present additional data from the Phase 2 clinical trial of KarXT for the treatment of acute psychosis in patients with schizophrenia.

Wednesday

Thursday

Lyra Therapeutics Inc (NASDAQ: LYRA)

Related Link: The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray

2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Continued here:
The Week Ahead In Biotech: ASCO Presentations In The Spotlight - Benzinga

Will there still be massage treatments? What the future of luxury spas looks like – Telegraph.co.uk

Meanwhile, SHA Wellness in Alicante, a global leader in integrated medical and preventative health, has just announced it will be reinforcing its treatments for the development of the immune system (which already includes immunotherapy, stem cell therapy, serum therapy, Vitamin C megadoses and stress management treatments) and require all guests to test for Covid-19 just before coming and have an anti-body test on arrival. It is also installing thermographic cameras for temperature detection in all guest and employee areas.

Ever the trailblazer, SHA is looking to schedule regular private jets to bring over groups of guests from international hubs such as London, Paris, Moscow and New York. It has also just announced it is launching a new app, SHA e-Health, which connects clients with key experts, for one-on-one sessions, on themes including regenerative, immune system-boosting medicine (45 minutes, 200) and emotional coaching sessions (50 minutes, 170).

So the industry will adapt. And there will be a rise in the popularity of treatments moving away from touch points from sound bath and gong therapy at Londons Mandrake Hotel to TRX (Total Body Resistance Exercise) deep in the cool, shadowy forest at Euphoria Retreat in Greece. And I for one, cant wait to go back.

Sign up for theTelegraphLuxurynewsletterfor your weekly dose of exquisite taste and expert opinion.

Original post:
Will there still be massage treatments? What the future of luxury spas looks like - Telegraph.co.uk